 |
|
This promotional message is being sent to you on behalf of Aerie Pharmaceuticals, Inc. |
|
|
|
|
|
|
|
A simple add or switch with one drop could mean improved outcomes for your patients. |
|
|
|
|
|
|
There's a reason you trust a PGA like latanoprost for your patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). But you also know that for some patients, a PGA alone isn't enough. A rho kinase (ROCK) inhibitor like Rhopressa® or a combination like Rocklatan® offers the next step from a PGA that may deliver additional efficacy from a single drop for your patients.1,2 |
|
 |
|
Adding Rhopressa® could provide consistent IOP reduction regardless of your patients’ current regimen3 |
|
|
|
When a PGA isn't enough to achieve sufficient IOP reduction, adding Rhopressa® will help your patients reach additional IOP reduction. Whether adding Rhopressa® to a PGA monotherapy, or to a combination of therapies, more patients may receive a consistent 20% IOP reduction beyond current treatment.1,3 |
|
Netarsudil—the active ingredient in Rhopressa®—is a first-in-class ROCK inhibitor that targets the trabecular meshwork to improve aqueous humor outflow1 and also decreases episcleral venous pressure (EVP).4 |
|
Please see below for Important Safety Information. |
|
|
 |
With mild and tolerable ocular side effects and no known contraindications, it can be safely used for patients who can't take or don't respond to a PGA.5,6,7 |
|
|
|
|
|
 |
|
Consider replacing your glaucoma patients’ PGA with once-daily Rocklatan®—the next step towards advancing IOP reduction2,8 |
|
|
|
As a powerful ROCK inhibitor, Rocklatan® brings together latanoprost, which targets the uveoscleral pathway, and netarsudil. Netarsudil targets the trabecular meshwork to improve aqueous humor outflow2 and also decreases episcleral venous pressure (EVP).4 Rocklatan® also offers superior IOP reduction compared to latanoprost or netarsudil alone.8 |
|
Please see below for Important Safety Information. |
|
|
 |
A simplified dosing regimen of one drop once daily could help your patients better adhere to their treatment.5 |
|
|
|
|
Find out more about how Rocklatan® and Rhopressa® can fit into your patients’ treatment plans. |
|
|
|
|
|
|
|
|
ROCKLATAN® IMPORTANT SAFETY INFORMATION |
Contraindications |
None. |
|
Warnings and Precautions |
|
|
• |
Intraocular inflammation |
|
|
|
|
|
|
Adverse reactions |
Rocklatan®: The most common ocular adverse reaction is conjunctival hyperemia (59%). Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients. |
|
Netarsudil 0.02%: Instillation site erythema, corneal staining, increased lacrimation and erythema of eyelid. |
|
Latanoprost 0.005%: Foreign body sensation, punctate keratitis, burning and stinging, itching, increased pigmentation of the iris, excessive tearing, eyelid discomfort, dry eye, eye pain, eyelid margin crusting, erythema of the eyelid, upper respiratory tract infection/nasopharyngitis/influenza, photophobia, eyelid edema, myalgia/arthralgia/back pain, and rash/allergic reaction. |
|
|
|
You are encouraged to report negative side effects of prescription drugs to the FDA. |
|
|
|
INDICATION |
Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. |
|
DOSAGE AND ADMINISTRATION |
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. |
|
|
|
|
|
|
RHOPRESSA® IMPORTANT SAFETY INFORMATION |
WARNINGS AND PRECAUTIONS |
Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. |
|
Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration. |
|
ADVERSE REACTIONS |
The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients. |
|
The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment. |
|
Please visit Rhopressa.com for full prescribing information for Rhopressa®. |
|
You are encouraged to report negative side effects of prescription drugs to the FDA. |
|
|
|
INDICATION |
Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. |
|
DOSAGE AND ADMINISTRATION |
The recommended dosage is one drop in the affected eye(s) once daily in the evening. |
|
References: |
|
1. |
Rhopressa® (netarsudil ophthalmic solution) 0.02% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019. |
|
|
2. |
Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2020. |
|
|
3. |
Data on file, Aerie Pharmaceuticals, Inc., Irvine, Calif. |
|
|
4. |
Kazemi A, McLaren JW, Kopczynski CC, et al. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34(5):380-386. |
|
|
5. |
Prum B Jr, Rosenberg L, Gedde S, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines. Ophthalmology. 2016;123(1):P41-P111. |
|
|
6. |
Serle JB, Katz LJ, McLaurin E, et al; and ROCKET-1 and ROCKET-2 Study Groups. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127. |
|
|
7. |
Khouri AS, Serle JB, Bacharach J, et al; for the ROCKET-4 Study Group. Once-daily netarsudil vs twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97-104. |
|
|
8. |
Asrani S, Robin A, Serle J, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;207:248-257. |
|
|
|
|
|
|
|
|
|
|
|
Please do not reply to this email. This mailbox is not monitored. |
|
©2020 Aerie Pharmaceuticals, Inc. All rights reserved. |
US-ROC-P-0043 |
|
|
|
|
|
|
|
